NO20004966L - Use of anti-gp-39 antibody in the treatment and / or reversal of lupus and associated kidney disease - Google Patents

Use of anti-gp-39 antibody in the treatment and / or reversal of lupus and associated kidney disease

Info

Publication number
NO20004966L
NO20004966L NO20004966A NO20004966A NO20004966L NO 20004966 L NO20004966 L NO 20004966L NO 20004966 A NO20004966 A NO 20004966A NO 20004966 A NO20004966 A NO 20004966A NO 20004966 L NO20004966 L NO 20004966L
Authority
NO
Norway
Prior art keywords
lupus
reversal
antibody
treatment
kidney disease
Prior art date
Application number
NO20004966A
Other languages
Norwegian (no)
Other versions
NO20004966D0 (en
Inventor
Randolph J Noelle
Christopher M Burns
Original Assignee
Dartmouth College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dartmouth College filed Critical Dartmouth College
Publication of NO20004966D0 publication Critical patent/NO20004966D0/en
Publication of NO20004966L publication Critical patent/NO20004966L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NO20004966A 1998-04-03 2000-10-02 Use of anti-gp-39 antibody in the treatment and / or reversal of lupus and associated kidney disease NO20004966L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5448898A 1998-04-03 1998-04-03
PCT/US1999/007321 WO1999051258A1 (en) 1998-04-03 1999-04-02 USE OF ANTI-gp39 ANTIBODIES FOR TREATMENT AND/OR REVERSAL OF LUPUS AND ASSOCIATED KIDNEY DISEASE

Publications (2)

Publication Number Publication Date
NO20004966D0 NO20004966D0 (en) 2000-10-02
NO20004966L true NO20004966L (en) 2000-12-04

Family

ID=21991433

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004966A NO20004966L (en) 1998-04-03 2000-10-02 Use of anti-gp-39 antibody in the treatment and / or reversal of lupus and associated kidney disease

Country Status (9)

Country Link
EP (1) EP1067954A4 (en)
JP (1) JP2002510643A (en)
KR (1) KR20010072564A (en)
CN (2) CN1173735C (en)
AU (1) AU743824B2 (en)
HU (1) HUP0101689A3 (en)
NO (1) NO20004966L (en)
TW (1) TWI224969B (en)
WO (1) WO1999051258A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41459A (en) 2015-02-03 2017-12-12 Als Therapy Development Inst ANTI-CD40L ANTIBODIES AND METHODS FOR TREATING CD40L ILLNESSES OR DISORDERS
PE20180802A1 (en) 2015-08-05 2018-05-09 Janssen Biotech Inc ANTI-CD154 ANTIBODIES AND METHODS OF USE OF THEM
KR20200010294A (en) 2017-05-24 2020-01-30 에이엘에스 테라피 디벨럽먼트 인스티튜트 Therapeutic Anti-CD40 Ligand Antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
CA2089229C (en) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
EE9900273A (en) * 1997-01-10 2000-02-15 Biogen, Incorporated Treatment of lupus nephritis with anti-CD40L compounds
AU5623398A (en) * 1997-03-07 1998-09-22 Biogen, Inc. Methods of therapeutic administration of anti-cd40l compounds
AU8266798A (en) * 1997-06-27 1999-01-19 Biogen, Inc. Cd154 blockade therapy for autoimmune diseases

Also Published As

Publication number Publication date
CN1173735C (en) 2004-11-03
EP1067954A4 (en) 2004-08-18
HUP0101689A3 (en) 2004-08-30
AU743824B2 (en) 2002-02-07
EP1067954A1 (en) 2001-01-17
CN1303301A (en) 2001-07-11
HUP0101689A2 (en) 2001-08-28
JP2002510643A (en) 2002-04-09
NO20004966D0 (en) 2000-10-02
CN100352497C (en) 2007-12-05
AU3379699A (en) 1999-10-25
TWI224969B (en) 2004-12-11
CN1757413A (en) 2006-04-12
KR20010072564A (en) 2001-07-31
WO1999051258A1 (en) 1999-10-14

Similar Documents

Publication Publication Date Title
FI970215A (en) Use of droloxifene in the treatment of prostate disease, endometriosis and obesity
NO20034437D0 (en) Ganglioside-associated recombinant antibodies and their use in the diagnosis and treatment of tumors
DE69836272D1 (en) EXPERIMENTAL ASSEMBLY FOR THE DETERMINATION OF ANALYTES IN BODY FLUIDS
NO991700D0 (en) Benzimidazole-2-carbamates for the treatment of viral infections and cancer
NO941440L (en) Oil well cement slurries, preparation of the slurries, and use in well cementing
HK1043625A1 (en) Kidney disease detection and treatment
EE05507B1 (en) Use of rosuvastatin ZD4522) in the treatment of heterosgococcal family h percolesterolemia
DK0745396T3 (en) Blood pump and its use
NO983576D0 (en) Well treatment fluids and methods
NO964075L (en) Immunotherapeutic agent and its use
DK1017408T3 (en) Use of tetrahydrolipstatin in the treatment of type II diabetes
NO20033443L (en) Use of CD-2 binding agents in the treatment or prevention of skin disorders
HUP0202048A3 (en) Use of alpha1betha1 integrin receptor inhibitors and tgf-betha1 inhibitors in the treatment of kidney disease
NO872302D0 (en) PESTICIDE MIXTURES AND PROCEDURES IN THE PREPARATION OF THESE.
NO951825D0 (en) Water based hair treatment preparation and its use
NO986034D0 (en) Combinations comprising VX 478, ZidovudÞn, FTC and / or 3TC for use
NO991160D0 (en) Sulfate-containing polysaccharides and their applications in medical treatment
IS2207B (en) Carbocyclic nucleus hemisulfate and its use in the treatment of viral infections
NO20020031D0 (en) Dihydrobenzodiazepines and their use in the treatment of dyslipidemia
NO20020207L (en) Biological materials and methods useful in the diagnosis and treatment of disease
PT1194038E (en) COMPOSITION OF BREACH OF THE REST AND ITS USE
NO20004966L (en) Use of anti-gp-39 antibody in the treatment and / or reversal of lupus and associated kidney disease
FI964809A0 (en) In the case of use of the processing unit
NO20011901D0 (en) Anti-convulsive derivatives useful in the treatment of alcohol dependence and abuse
NO890816L (en) DEEMULATING MIXTURES AND PROCEDURES IN THE PREPARATION AND APPLICATION OF THEREOF.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application